Klinische Studien für Kolorektalkarzinome

Sie befinden sich hier:

  • MK-3475-177
    Phase-III-Studie zu Pembrolizumab (MK-3475) gegen Chemotherapie bei Kolorektalkarzinom in Stadium IV mit hoher Mikrosatelitenstabilität (MSI-H) oder mit einem fehlerhaften Mismatch-Reparatur-System (dMMR)
    Synopse
  • PARLIM
    Panitumumab after Resection of Liver Metastases from Colorectal Cancer in KRAS Wild-type Patients
    Synopse
  • AVETUX-CRC
    Avelumab and cetuximab in combination with FOLFOX in ptients with previosly untreated metastatic colorectal cancer-The phase II AVETUX-CRC trial
  • CanStem303C
    A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) with or without Bevacizumab in adult patients with previously treated metastatic colorectal cancer
    Synopse
  • T-VEC+ Atezolizumab
    Phase 1b Study of Talimogene Laherparepvec in Combination with Atezolizumab in Subjects with triple negative breast cancer and colorectal cancer with liver metastases
  • PanaMA AIO-KRK-0212
    phase II,Randomised study for evaluation of efficacy and safety of maintenance treatment with 5 -FU/FA plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancer
    Synopse

Ansprechpartner im Studiensekretariat Onkologie

Isabell Grüttner

Studiensekretariat OnkologieCharitéUniversitätsmedizin Berlin

Susanne Grüneberg

Studiensekretariat OnkologieCharitéUniversitätsmedizin Berlin